DK2740794T3 - Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer - Google Patents
Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer Download PDFInfo
- Publication number
- DK2740794T3 DK2740794T3 DK12820091.2T DK12820091T DK2740794T3 DK 2740794 T3 DK2740794 T3 DK 2740794T3 DK 12820091 T DK12820091 T DK 12820091T DK 2740794 T3 DK2740794 T3 DK 2740794T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- gin
- cancer
- leu
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Antistof eller fragment deraf, der har immunologisk reaktivitet med et CAP-RIN-1-protein, hvor antistoffet eller fragmentet deraf omfatter en tungkæde-variabel region omfattende komplementaritetsbestemmende regioner afSEQ ID NOs: 5, 6 og 7 og en letkæde-variabel region omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 9, 10 og 11.
2. Antistof eller fragment deraf ifølge krav 1, hvor antistoffet er et humaniseret antistof, et kimært antistof, et enkeltkædet antistof eller et multispecifikt antistof.
3. Antistof eller fragment deraf ifølge krav 1 eller 2, hvor antistoffet eller fragmentet deraf er konjugeret med et antitumormiddel.
4. Antistof eller fragment deraf ifølge et hvilket som helst af de foregående krav til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer.
5. Antistof eller fragment deraf til anvendelse ifølge krav 4, hvor cancertypen er brystcancer, nyrecancer, pancreascancer, tyktarmscancer, lungecancer, hjernetumor, mavecancer, livmoderhalscancer, æggestokcancer, prostata-cancer, urinblærecancer, spiserørscancer, leukæmi, lymfom, fibrosarkom, ma-stocytom eller melanom.
6. Farmaceutisk sammensætning omfattende et antistof eller et fragment deraf ifølge et hvilket som helst af kravene 1 til 3 som en aktiv bestanddel.
7. Farmaceutisk sammensætning ifølge krav 6 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 7, hvor cancertypen er brystcancer, nyrecancer, pancreascancer, tyktarmscancer, lungecancer, hjernetumor, mavecancer, livmoderhalscancer, æggestokcancer, prosta-tacancer, urinblærecancer, spiserørscancer, leukæmi, lymfom, fibrosarkom, mastocytom eller melanom.
9. Farmaceutisk kombination omfattende en farmaceutisk sammensætning ifølge krav 6 og en farmaceutisk sammensætning, der omfatter et antitumormiddel.
10. Farmaceutisk kombination ifølge krav 9 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer.
11. Farmaceutisk kombination til anvendelse ifølge krav 10, hvor cancertypen er brystcancer, nyrecancer, pancreascancer, tyktarmscancer, lungecancer, hjernetumor, mavecancer, livmoderhalscancer, æggestokcancer, prostata-cancer, urinblærecancer, spiserørscancer, leukæmi, lymfom, fibrosarkom, mastocytom eller melanom.
12. DNA, der koder for et antistof eller et fragment deraf ifølge krav 1 eller 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171377 | 2011-08-04 | ||
| PCT/JP2012/069853 WO2013018891A1 (ja) | 2011-08-04 | 2012-08-03 | 癌の治療及び／又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2740794T3 true DK2740794T3 (da) | 2018-06-14 |
Family
ID=47629405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12820091.2T DK2740794T3 (da) | 2011-08-04 | 2012-08-03 | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9175074B2 (da) |
| EP (1) | EP2740794B1 (da) |
| JP (1) | JP6065590B2 (da) |
| KR (1) | KR101980557B1 (da) |
| CN (1) | CN103717739B (da) |
| AU (1) | AU2012290954B2 (da) |
| BR (1) | BR112014002613B1 (da) |
| CA (1) | CA2844040C (da) |
| DK (1) | DK2740794T3 (da) |
| ES (1) | ES2672695T3 (da) |
| HU (1) | HUE039219T2 (da) |
| MX (1) | MX348578B (da) |
| PL (1) | PL2740794T3 (da) |
| PT (1) | PT2740794T (da) |
| RU (1) | RU2610428C2 (da) |
| TR (1) | TR201808595T4 (da) |
| WO (1) | WO2013018891A1 (da) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2322221T3 (pl) | 2008-08-05 | 2015-01-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i zapobiegania raka |
| HUE027332T2 (en) | 2008-08-05 | 2016-09-28 | Toray Industries | Cancer Detection Method |
| PT2532743E (pt) | 2010-02-04 | 2015-08-04 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro |
| AU2012290949B2 (en) * | 2011-08-04 | 2017-03-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| RU2624040C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Способ обнаружения рака поджелудочной железы |
| RU2631804C2 (ru) | 2012-02-21 | 2017-09-26 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения или профилактики рака |
| ES2656620T3 (es) * | 2012-03-30 | 2018-02-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| PL2876447T3 (pl) * | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| PL2876446T3 (pl) | 2012-07-19 | 2019-06-28 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| US9862774B2 (en) | 2013-08-09 | 2018-01-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| RU2655461C2 (ru) * | 2013-12-26 | 2018-05-28 | Витро, С.А.Б. Де С.В. | Органический светоизлучающий диод с испускающим свет электродом |
| EP3484518B1 (en) | 2016-07-07 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Antibody adjuvant conjugates |
| WO2018079740A1 (ja) | 2016-10-28 | 2018-05-03 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| MX2020009862A (es) | 2018-03-30 | 2020-10-08 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| CN113993549A (zh) | 2019-03-15 | 2022-01-28 | 博尔特生物治疗药物有限公司 | 靶向her2的免疫缀合物 |
| JP7281951B2 (ja) * | 2019-04-22 | 2023-05-26 | シャープ株式会社 | 電子機器、制御装置、制御プログラムおよび制御方法 |
| CA3142887A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| AU2020359446A1 (en) | 2019-09-30 | 2022-04-21 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| JP2022553702A (ja) | 2019-10-25 | 2022-12-26 | ボルト バイオセラピューティクス、インコーポレーテッド | チエノアゼピン、イムノコンジュゲート、及びそれらの使用 |
| WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CA3175137A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US20230140155A1 (en) | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4119160A4 (en) | 2020-03-12 | 2024-04-03 | Toray Industries, Inc. | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| BR112022018166A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
| JP2023524271A (ja) | 2020-05-08 | 2023-06-09 | ボルト バイオセラピューティクス、インコーポレーテッド | エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用 |
| MX2023001679A (es) | 2020-08-13 | 2023-02-22 | Bolt Biotherapeutics Inc | Inmunoconjugados de pirazolazepina y usos de estos. |
| AU2022298240A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2022296193A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023008461A1 (da) | 2021-07-27 | 2023-02-02 | ||
| KR20240042416A (ko) | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| MX2024002571A (es) | 2021-09-03 | 2024-03-20 | Toray Industries | Composicion farmaceutica para tratamiento y/o prevencion de cancer. |
| EP4422697A1 (en) | 2021-10-29 | 2024-09-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| CA2325346A1 (en) | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| KR20070112860A (ko) | 1998-07-14 | 2007-11-27 | 코릭사 코포레이션 | 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법 |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| JP2002540790A (ja) | 1999-04-02 | 2002-12-03 | コリクサ コーポレイション | 肺癌の治療および診断のための化合物ならびにその使用のための方法 |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| CA2404233A1 (en) | 2000-03-29 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| PT1354034E (pt) | 2000-11-30 | 2008-02-28 | Medarex Inc | Roedores transgénicos transcromossómicos para produção de anticorpos humanos |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| CA2504144A1 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the diagnosis of immune related diseases using pro7 |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| EP1629119A2 (en) | 2003-04-29 | 2006-03-01 | Wyeth | Methods for diagnosing aml and mds by differential gene expression |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| WO2005116076A2 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
| EP1735348B1 (en) | 2004-03-19 | 2012-06-20 | Imclone LLC | Human anti-epidermal growth factor receptor antibody |
| AU2005229457B2 (en) | 2004-03-30 | 2010-11-25 | Glaxo Group Limited | Immunoglobulins |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| BRPI0518104B8 (pt) | 2005-01-21 | 2021-05-25 | Genentech Inc | artigo industrializado e uso de anticorpo her2 |
| US7858324B2 (en) | 2005-02-18 | 2010-12-28 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| MX2007011024A (es) | 2005-03-11 | 2009-11-23 | Vermillion Inc | Biomarcadores para cancer de ovario y cancer de endometrio: hepcidin. |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| US8211634B2 (en) | 2006-02-14 | 2012-07-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008044754A1 (fr) * | 2006-10-06 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Agent prophylactique ou thérapeutique pour le cancer |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| PL2324842T3 (pl) | 2008-08-05 | 2015-08-31 | Toray Industries | Środek indukujący odporność |
| PL2322221T3 (pl) | 2008-08-05 | 2015-01-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i zapobiegania raka |
| HUE027332T2 (en) | 2008-08-05 | 2016-09-28 | Toray Industries | Cancer Detection Method |
| CA2771441C (en) | 2009-08-19 | 2016-10-11 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| PT2532743E (pt) | 2010-02-04 | 2015-08-04 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro |
| US9180187B2 (en) | 2010-02-04 | 2015-11-10 | Toray Industries, Inc. | Medicament for treating and/or preventing cancer |
| PL2532366T3 (pl) | 2010-02-04 | 2017-02-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi |
| BR112012019098B8 (pt) | 2010-02-04 | 2021-08-17 | Toray Industries | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica |
| ES2583627T3 (es) | 2010-02-04 | 2016-09-21 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| ES2583777T3 (es) | 2010-02-04 | 2016-09-22 | Toray Industries, Inc. | Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer |
| JP2011171377A (ja) | 2010-02-16 | 2011-09-01 | Covalent Materials Corp | シリコンウェーハの製造方法 |
| RU2624040C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Способ обнаружения рака поджелудочной железы |
| AU2012290949B2 (en) | 2011-08-04 | 2017-03-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| ES2763122T3 (es) | 2011-08-04 | 2020-05-27 | Toray Industries | Composición farmacéutica, que comprende anticuerpos contra caprin 1 para el tratamiento y/o para la prevención del cáncer |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| ES2656620T3 (es) | 2012-03-30 | 2018-02-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado |
-
2012
- 2012-08-03 TR TR2018/08595T patent/TR201808595T4/tr unknown
- 2012-08-03 PL PL12820091T patent/PL2740794T3/pl unknown
- 2012-08-03 PT PT128200912T patent/PT2740794T/pt unknown
- 2012-08-03 BR BR112014002613-0A patent/BR112014002613B1/pt active IP Right Grant
- 2012-08-03 AU AU2012290954A patent/AU2012290954B2/en active Active
- 2012-08-03 DK DK12820091.2T patent/DK2740794T3/da active
- 2012-08-03 RU RU2014108043A patent/RU2610428C2/ru active
- 2012-08-03 HU HUE12820091A patent/HUE039219T2/hu unknown
- 2012-08-03 EP EP12820091.2A patent/EP2740794B1/en active Active
- 2012-08-03 US US14/236,859 patent/US9175074B2/en active Active
- 2012-08-03 ES ES12820091.2T patent/ES2672695T3/es active Active
- 2012-08-03 WO PCT/JP2012/069853 patent/WO2013018891A1/ja active Application Filing
- 2012-08-03 KR KR1020147005859A patent/KR101980557B1/ko active IP Right Grant
- 2012-08-03 CN CN201280038467.4A patent/CN103717739B/zh active Active
- 2012-08-03 CA CA2844040A patent/CA2844040C/en active Active
- 2012-08-03 JP JP2012543816A patent/JP6065590B2/ja active Active
- 2012-08-03 MX MX2014001371A patent/MX348578B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012290954A1 (en) | 2014-03-20 |
| PT2740794T (pt) | 2018-06-14 |
| CN103717739B (zh) | 2015-07-29 |
| KR20140054180A (ko) | 2014-05-08 |
| PL2740794T3 (pl) | 2018-09-28 |
| MX348578B (es) | 2017-06-20 |
| HUE039219T2 (hu) | 2018-12-28 |
| US20140154261A1 (en) | 2014-06-05 |
| CA2844040A1 (en) | 2013-02-07 |
| AU2012290954B2 (en) | 2017-08-31 |
| CA2844040C (en) | 2019-05-07 |
| RU2014108043A (ru) | 2015-09-10 |
| MX2014001371A (es) | 2014-03-21 |
| CN103717739A (zh) | 2014-04-09 |
| KR101980557B1 (ko) | 2019-05-21 |
| ES2672695T3 (es) | 2018-06-15 |
| RU2610428C2 (ru) | 2017-02-10 |
| EP2740794A1 (en) | 2014-06-11 |
| JPWO2013018891A1 (ja) | 2015-03-05 |
| JP6065590B2 (ja) | 2017-01-25 |
| WO2013018891A1 (ja) | 2013-02-07 |
| TR201808595T4 (tr) | 2018-07-23 |
| EP2740794B1 (en) | 2018-04-04 |
| BR112014002613B1 (pt) | 2022-08-23 |
| US9175074B2 (en) | 2015-11-03 |
| EP2740794A4 (en) | 2015-04-22 |
| BR112014002613A2 (pt) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2740794T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2740798T3 (da) | Lægemiddelsammensætning til cancerbehandling og/eller forebyggelse | |
| DK2818483T3 (da) | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2740795T3 (da) | Lægemiddelsammensætning til behandling og/eller forebyggelse af cancer | |
| DK2740793T3 (da) | Lægemiddelsammensætning til cancerbehandling og/eller -forebyggelse | |
| AU2013223143B2 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| DK2740796T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| CA2864999C (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| AU2013223147A1 (en) | Pharmaceutical composition for treatment and/or prevention of cancer |